Interview with Thierry Poiraud, General Manager, Menarini France
This year Menarini will launch several new products in France to add to its current portfolio. Apart from this, can you tell us about activities and position in France? Our…
Address: Menarini Building 1 rue du Jura 94633 Rungis Cedex BP 40528, France
Tel: 01 45 60 77 20
Web: http://www.menarini.fr/accueil/
Menarini started up its operations in Feb 1992 with a product portfolio acquired through an exchange of products with Sanofi. From this base, the affiliate ventured onto the French market and in 1993 it launched an original gel with analgesic and anti-inflammatory properties, and in a few months time it became the leader in this therapeutic class. Three innovative cardiovascular products have been launched successively in 2002 and 2004.
MENARINI, 1 Italian pharmaceutical group, today operates in over 100 countries. With over 2.6 billion euros in turnover, 12 500 employees, the Menarini Group is the 20th in European rankings and 36th in the world rankings.
France: 112.5 million euros in 2008; employs 600 (heavy growth in last 5 years, double # last 3 years and wants 150m euro for 2010)
Distribution of turnover: 30% Self-Medication – Ethical Drugs 70%
Commercial/Mkting autonomy for HQ
2 launches in 2009: cardiology, angina pectoris
Sports medicine and Rhumatology in France
Present in the most important therapeutic areas of greatest importance, including:
• Cardiovascular Products
• Gastro-intestinal Products
• Antibiotics / Respiratory System Products
• Diabetes
• Anti-inflammatory agents / Analgesics
This year Menarini will launch several new products in France to add to its current portfolio. Apart from this, can you tell us about activities and position in France? Our…
Joël Jaouen, president of France Alzheimer, provides important insights into the role and objectives of the patient association. He explains why France Alzheimer together with other learned societies filed a…
PharmaBoardroom’s list of personalities whose voices, opinions and decisions matter in French pharma’s industry, regulatory affairs, reimbursement and pricing. Maurice-Pierre Planel — President of CEPS Maurice-Pierre Planel Has been…
Lundbeck France and Benelux’s Lourdes Pla discusses Europe-wide restructuring, the importance of the French affiliate to the global group and the government’s attitude towards healthcare and neuroscience. We are…
Gérard Raymond, president of the Fédération Francaise des Diabétiques (FFD – French Diabetes Federation), gives an update on the situation of diabetes in France and explains the challenges for patient…
Christophe Cizeron, president of Lyonbiopole, discusses the important economic and industrial position of the research cluster in the Rhone-Alps Region as well as the challenges posed by domestic and international…
Vincent Leonhardt explains how the French administration’s zeal for life science innovation can actually place pressure on some pharma SMEs. He also discusses the challenges he faced during his first…
Pierre Moustial, CEO of URGO Group, explains the life-changing advancement in wound care treatments that URGO has been providing to patients all over the world as well as his upcoming…
Thomas Courbe, general director of the DGE (Direction Générale des Entreprises – General Directorate for Enterprises), speaks about the role of the DGE and the implementation of new policies oriented…
Stéphane Roques, CEO of Medicen, the health care cluster for the Paris region, discusses his vision for Medicen and the changes he has made during his first few months in…
Pierre Moustial, chairman of MedTech in France, the association of medical technology companies in France, discusses the challenges for French healthcare start-ups to scale-up and explains why France has no…
Frédérique Vidal, the French Minister of Higher Education, Research and Innovation, discusses her plans to create innovation campuses to facilitate the collaboration between industry, institutes and academia. She also highlights…
Cancer is the leading cause of death in France, accounting for 28.5% of all deaths in 2014, followed by cardiovascular diseases, which accounted for 25%. However, there are gender differences:…
See our Cookie Privacy Policy Here
